The purpose of this Phase III study is to evaluate the efficacy and safety of 3APS compared to placebo (inactive substance pill) in patients with mild to moderate Alzheimer's disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
950
The two primary efficacy parameters are the change from baseline to month 18 in the Alzheimer's Disease Assessment Scale, cognitive subpart (ADAS-cog) and the clinical Deterioration Scale Sum of Boxes (CDR-SB) scores.
The brain volume change from baseline as measured by Magnetic Resonance Imaging will also be assessed.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pivotal Research Centers
Peoria, Arizona, United States
21st Century Neurology, a division of Xenoscience
Phoenix, Arizona, United States
Central Arkansas Research
Hot Springs, Arkansas, United States
Margolin Brain Institute
Fresno, California, United States
Senior Clinical Trials, Inc.
Laguna Hills, California, United States
Pacific Research Network, Inc.
San Diego, California, United States
San Francisco Clinical Research Center
San Francisco, California, United States
Radiant Research
Denver, Colorado, United States
Research Center for Clinical Studies, Inc.
Darien, Connecticut, United States
Yale University, Alzheimer's Disesase Research Unit
New Haven, Connecticut, United States
...and 57 more locations